Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.73 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.73 |
| ▸ | DPP4 | P27487 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.73 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.73 |
| ▸ | GAPDH | P04406 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | STAT6 | P42226 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.73 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.73 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.73 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.73 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859780 | 1.00 | ADORA1 (0.73) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL9426538 | 0.91 | PRKACA (0.73) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2463542 | 0.91 | PRKACA (0.73) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL5550634 | 0.90 | P2RY1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL31001632 | 0.90 | P2RY1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL219554 | 0.90 | P2RY1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL11584743 | 0.90 | P2RY1 (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL9295626 | 0.89 | AHCY (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL9295615 | 0.89 | AHCY (0.71) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B | |
| SCHEMBL2790606 | 0.89 | PLA2G2A (0.68) | ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943760-B2 | Non-nucleotide composition for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100197913-A1 | NON-NUCLEOTIDE COMPOSITION FOR INHIBITING PLATELET AGGREGATION | PLOURDE JR ROBERT | 2010-08-05 | — | — | US | disclosed |
| US-7749980-B2 | Non-nucleotide compositions and method for treating pain | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7749981-B2 | Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound | INSPIRE PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7592445-B2 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1943261-A2 | DRUG-ELUTING STENTS COATED WITH NON-NUCLEOTIDE P2Y12 RECEPTOR ANTAGONIST COMPOUND | Inspire Pharmaceuticals, Inc. (US) | 2008-07-16 | — | — | EP | disclosed |
| US-7368438-B2 | Non-nucleotide compositions and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080103304-A1 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | PLOURDE ROBERT JR | 2008-05-01 | — | — | US | disclosed |
| US-7335648-B2 | Non-nucleotide composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1883637-A2 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | Inspire Pharmaceuticals, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| US-6335320-B1 | Method of treating fibrotic conditions | UCB S.A. (BE) | 2002-01-01 | — | — | US | disclosed |
| EP-1111065-A2 | Production of saccharide carboxylic acids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5635611-A | COMPLEXING DETRANYLGLUCURONIC ACID SALT WITH FERRIC HYDROXIDE SOL TO FORM A COMPLEX; RESISTANT TO ENZYMATIC DEGRADATION AND IMPROVED WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5635610-A | FROM OXIDATION BY A MICROORGANISM BELONGING TO THE GENUS PSEUDOGLUCONOBACTER; RESISTANT TO ENZYMATIC DEGRADATION; IMPROVED WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-06-03 | — | — | US | disclosed |
| US-5629411-A | RESISTANT TO ENZYMATIC DEGRATION, IMPROVED WATER SOLUBILITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| US-5434061-A | Pseudogluconobacter | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-07-18 | — | — | US | disclosed |
| EP-0599646-A2 | Production of saccharide carboxylic acids | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103304-A1 | NON-NUCLEOTIDE COMPOSITION AND METHOD FOR INHIBITING PLATELET AGGREGATION | P2RY12, P2RY11, P2RY13 | ADORA1 21/4885SMN1; SMN2 3640/4885ADORA3 19/4885 |
| US-20100197913-A1 | NON-NUCLEOTIDE COMPOSITION FOR INHIBITING PLATELET AGGREGATION | P2RY12, P2RY13, P2RY11 | ADORA1 23/4885SMN1; SMN2 3502/4885ADORA3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.